ALEXANDRIA, Va., Jan. 28 -- United States Patent no. 12,534,538, issued on Jan. 27, was assigned to Certis Therapeutics Pty Ltd (Kew East, Australia).
"Anti-HER2 binding molecules" was invented by Andrew Mark Scott (Kew East, Australia), Hui Kong Gan (Kew East, Australia), Zhanqi Liu (Kew East, Australia) and Sagun Parakh (Kew East, Australia).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure is directed to binding proteins to the extracellular domain (ECD) of HER2/ErbB2. More particularly, the binding proteins bind to a conformational epitope which is exposed in cells in response to HER2 amplification or activation."
The patent was filed on March 20, 2020, under Application No. 17/442,07...